NOVA:FRA
Novo Nordisk A/S
€33.64
arrow_upward
+1.26%(+0.42) 1D
Okt 7, 11:46:52 AM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa NOVA...
Buksan
€33.16
Mataas
€33.64
Mababa
€32.94
Mkt. cap
127.72B
Avg. na dami
1.28K
Dami
635.00
Mataas nang 52-wk
€54.80
Mababa nang 52-wk
€30.45
Bilang ng mga empleyado
67K
Buksan
€33.16
Mataas
€33.64
Mababa
€32.94
Mkt. cap
127.72B
Avg. na dami
1.28K
Dami
635.00
Mataas nang 52-wk
€54.80
Mababa nang 52-wk
€30.45
Bilang ng mga empleyado
67K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Foreign Policy Journal
·
15 minuto ang nakalipas
Novo Nordisk (NYSE: NVO) Stock Sits 70% Below Its Peak — Value Trap Or Generational Buying Opportunity?
AD HOC NEWS
·
1 oras ang nakalipas
Novo Nordisk stock reports 7 percent Q2 sales growth
NAI500
·
6 oras ang nakalipas
Novo Nordisk Stock Has Fallen Sharply, Does a Long-Term Opportunity Emerge?
AD HOC NEWS
·
7 oras ang nakalipas
Novo Nordisk stock pre-market at EUR 33.40: plus 0.54 percent
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
Tungkol sa Novo Nordisk A/S
CEOMaziar Mike Doustdar
Mga Empleyado66.7K
ItinatagDis 21, 1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
Sektor-
Websitenovonordisk.com